Your browser doesn't support javascript.
loading
Correction: Treatment-free remission after a second TKI discontinuation attempt in patients with Chronic Myeloid Leukemia re-treated with dasatinib - interim results from the DAstop2 trial.
Flygt, Hjalmar; Söderlund, Stina; Richter, Johan; Saussele, Susanne; Koskenvesa, Perttu; Stenke, Leif; Mustjoki, Satu; Dimitrijevic, Andreja; Stentoft, Jesper; Majeed, Waleed; Roy, Lydia; Wolf, Dominik; Dreimane, Arta; Gjertsen, Bjørn Tore; Gedde-Dahl, Tobias; Ahlstrand, Erik; Markevärn, Berit; Hjorth-Hansen, Henrik; Janssen, Jeroen; Olsson-Strömberg, Ulla.
Afiliação
  • Flygt H; Department of Medical Science and Division of Hematology, Uppsala University Hospital, Uppsala, Sweden. hjalmar.flygt@medsci.uu.se.
  • Söderlund S; Department of Medical Science and Division of Hematology, Uppsala University Hospital, Uppsala, Sweden.
  • Richter J; Department of Hematology, Oncology and Radiation Physics, Skåne University Hospital, Lund, Sweden.
  • Saussele S; Medical Clinic, Medical Faculty Mannheim of the University of Heidelberg, Mannheim, Germany.
  • Koskenvesa P; Department of Hematology, Hematology Research Unit Helsinki and Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland.
  • Stenke L; Department of Hematology, Karolinska University Hospital and Department of Medicine, Karolinska Institutet, Stockholm, Sweden.
  • Mustjoki S; Department of Hematology, Hematology Research Unit Helsinki and Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland.
  • Dimitrijevic A; Translational Immunology Research Program and Department of Clinical Chemistry and Hematology, University of Helsinki, Helsinki, Finland.
  • Stentoft J; ICAN Digital Precision Cancer Medicine Flagship, Helsinki, Finland.
  • Majeed W; Department of Hematology, Odense University Hospital, Odense, Denmark.
  • Roy L; Department of Hematology, Aarhus University Hospital, Aarhus, Denmark.
  • Wolf D; Department of Hemato-Oncology, Stavanger University Hospital, Stavanger, Norway.
  • Dreimane A; French CML group Fi-LMC, Centre Léon Bérard, Lyon, Hôpital Universitaire Henri Mondor, AP-HP, Service d'hématologie Clinique & Faculté de Santé, Université Paris Est Créteil, Créteil, France.
  • Gjertsen BT; Department of Hematology and Oncology, Comprehensive Cancer Center Innsbruck (CCCI), Tyrolean Cancer Research Institute (TKFI), Medical University Innsbruck, Innsbruck, Austria.
  • Gedde-Dahl T; Medical Clinic 3, Universitätsklinikum, Bonn, Germany.
  • Ahlstrand E; Department of Hematology, Linköping University Hospital, Linköping, Sweden.
  • Markevärn B; Department of Internal Medicine, Hematology Section, Haukeland University Hospital, Bergen, Norway.
  • Hjorth-Hansen H; Department of Hematology, Oslo University Hospital, Rikshospitalet, Oslo, Norway.
  • Janssen J; Department of Medicine, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.
  • Olsson-Strömberg U; Department of Hematology, Umeå University Hospital, Umeå, Sweden.
Leukemia ; 38(4): 925, 2024 Apr.
Article em En | MEDLINE | ID: mdl-38418611
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Revista: Leukemia Assunto da revista: HEMATOLOGIA / NEOPLASIAS Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Suécia
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Revista: Leukemia Assunto da revista: HEMATOLOGIA / NEOPLASIAS Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Suécia